Learn More
BACKGROUND Myocardial fibrosis (MF) occurs in up to 80% of subjects with asymptomatic or mildly symptomatic hypertrophic cardiomyopathy (HCM) and can constitute an arrhythmogenic substrate for re-entrant, life-threatening ventricular arrhythmias in predisposed persons. OBJECTIVE The aim was to investigate whether MF detected by delayed enhancement cardiac(More)
BACKGROUND Myocardial stress CT perfusion (CTP) can detect myocardial ischemia. OBJECTIVE We evaluated the transmural perfusion ratio (TPR) of dipyridamole stress CTP to detect significant coronary stenosis (>70%) defined by quantitative invasive coronary angiography (ICA). METHODS Twenty-six patients (61.6 ± 8.0 years old; 14 males), without prior(More)
BACKGROUND The stratification of risk for sudden death in hypertrophic cardiomyopathy (HCM) continues to be a true challenge due to the great heterogeneity of this disease's presentation, as most individuals remain asymptomatic during their entire lives and others present sudden death as first symptom. Recent studies have suggested that myocardial fibrosis(More)
Effects of can-desartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. of all-cause heart failure and borderline left ventricular systolic dysfunction: 5-year mortality follow-up of the Echocardiographic A 48-year-old woman presented worsening of dyspnoea in the previous 6 months.(More)
OBJECTIVE The toxicity of anti-cancer chemotherapeutic agents can be reduced by associating these compounds, such as the anti-proliferative agent paclitaxel, with a cholesterol-rich nanoemulsion (LDE) that mimics the lipid composition of low-density lipoprotein (LDL). When injected into circulation, the LDE concentrates the carried drugs in neoplastic(More)
  • 1